Mylan boasts of 16 biosimilars in portfolio after Mabion rituximab deal
Mylan has struck a deal to commercialise a version of Roche’s Mabthera in Europe made by Polish biotech Mabion using a 2,500L disposable bioreactor system.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs